Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study.

Guo-Ming ShiXiao-Yong HuangTian-Fu WenTian-Qiang Song Ming KuangHai-Bo MouLe-Qun BaoHai-Tao ZhaoHaitao ZhaoXie-Lin FengBi-Xiang ZhangTao PengYu-Bao ZhangXiang-Cheng LiHong-Sheng YuYu CaoLian-Xin LiuTi ZhangWei-Lin WangJiang-Hua RanYing-Bin LiuWei GongMing-Xia ChenLian CaoYang LuoYan WangHui ZhouGuo-Huan YangJia Fan Jian Zhou

Published in: Cancer medicine (2022)

The encouraging antitumor activity and favorable safety profile support the use of pemigatinib as a treatment in previously treated Chinese patients with cholangiocarcinoma and FGFR2 rearrangements.

Keyphrases

phase ii study
locally advanced
squamous cell carcinoma
rectal cancer
neoadjuvant chemotherapy
radiation therapy
open label
small cell lung cancer
newly diagnosed
placebo controlled
lymph node
combination therapy
study protocol
double blind